CRSP vs EDIT Stock Comparison: AI Score, Valuation, Performance and Upside
CRSP is the clear leader in the CRISPR gene editing space having achieved the first-ever CRISPR therapy approval (Casgevy) with Vertex Pharmaceuticals, while EDIT is an earlier-stage gene editing company with clinical programs still working toward proving its approach. Both face the broader challenges of gene therapy commercialization, but CRSP has a meaningful head start.
CRSP vs EDIT compares the leading CRISPR gene editing company with a commercially approved therapy against an earlier-stage CRISPR competitor still advancing programs through clinical development.
EDIT holds the edge across 4 of 5 key metrics in this comparison. EDIT leads on both 1-year return (0.00%) and forward P/E quality (-4.04x vs -16.10x for CRSP), a relatively favorable combination of momentum and valuation. On fundamentals, CRSP is growing revenue faster (1041.40%), while EDIT maintains the higher operating margin (-167.31%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for EDIT (+97.04%) than for CRSP (+55.54%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to the gene editing company that achieved the first CRISPR therapy approval
- Value the Vertex partnership for financial backing and commercial infrastructure
- Believe CRISPR-based cures will build into meaningful commercial franchises
- Want earlier-stage exposure to in vivo CRISPR gene editing technology
- See potential value in Editas's foundational IP and clinical programs at a smaller valuation
- Are comfortable with higher clinical and execution risk in exchange for earlier-stage upside
| Metric | CRSP | EDIT |
|---|---|---|
| AI scorei | 45.4 | 26.6 |
| AI ranki | #699 | #2470 |
| Latest closei | $58.33 | $2.83 |
| 1M returni | -1.97% | -9.00% |
| 6M returni | +24.42% | +17.92% |
| 1Y returni | -6.40% | 0.00% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | CRSP | EDIT |
|---|---|---|
| 1Y ago | $9.39K (-6.1%) started 2025-09-22 | $9.43K (-5.7%) started 2025-09-22 |
| 5Y ago | $4.97K (-50.3%) started 2021-09-21 | $482.28 (-95.2%) started 2021-09-21 |
| 10Y ago | $41.4K (+314.0%) started 2016-10-19 | $1.89K (-81.1%) started 2016-09-21 |
Hypothetical — past performance does not guarantee future results.
| Metric | CRSP | EDIT |
|---|---|---|
| Market capi | $5.44B | $467.65M |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -16.10 | -4.04 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 292.23 | 5.86 |
| Analyst targeti | $87.56 | $6.00 |
| Target upsidei | +55.54% | +97.04% |
| Metric | CRSP | EDIT |
|---|---|---|
| Revenue growthi | 1041.40% | 232.30% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | -1611.75% | -94.28% |
| Operating margini | -1127.55% | -167.31% |
| Profit margini | 0.00% | -157.32% |
| ROIC proxyi | -26.10% | -118.82% |
| Return on equityi | -26.10% | -118.82% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 1.74 | 2.06 |
| Debt/equityi | 44.87 | 14.73 |
| Current ratioi | 17.85 | 3.19 |
| Quick ratioi | 17.79 | 3.13 |
Over the past year, CRSP and EDIT have moved moderately in the same direction (correlation of 0.63), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | CRSP | EDIT |
|---|---|---|---|
| 1Y | Growthi | -6.07% | -5.67% |
| CAGRi | -6.09% | -5.69% | |
| Volatilityi | 59.66% | 83.58% | |
| Sharpe ratioi | 0.12 | 0.29 | |
| Sortino ratioi | 0.17 | 0.44 | |
| Max drawdowni | 42.25% | 59.88% | |
| Current drawdowni | 24.03% | 31.81% | |
| Avg drawdowni | 27.67% | 33.36% | |
| Ulcer Indexi | 29.13% | 36.26% | |
| Max daily dropi | 11.59% | 15.57% | |
| Max wkly dropi | 18.19% | 22.13% | |
| 5Y | Growthi | -50.25% | -95.18% |
| CAGRi | -13.03% | -45.47% | |
| Volatilityi | 60.91% | 93.46% | |
| Sharpe ratioi | -0.00 | -0.26 | |
| Sortino ratioi | -0.00 | -0.41 | |
| Max drawdowni | 74.21% | 98.42% | |
| Current drawdowni | 51.89% | 95.44% | |
| Avg drawdowni | 52.97% | 86.09% | |
| Ulcer Indexi | 54.06% | 87.23% | |
| Max daily dropi | 13.32% | 35.63% | |
| Max wkly dropi | 21.49% | 42.50% | |
| 10Y | Growthi | +313.98% | -81.06% |
| CAGRi | +15.39% | -15.33% | |
| Volatilityi | 64.04% | 84.13% | |
| Sharpe ratioi | 0.47 | 0.15 | |
| Sortino ratioi | 0.73 | 0.24 | |
| Max drawdowni | 85.11% | 98.92% | |
| Current drawdowni | 72.23% | 96.88% | |
| Avg drawdowni | 49.91% | 61.03% | |
| Ulcer Indexi | 56.41% | 69.08% | |
| Max daily dropi | 17.10% | 35.63% | |
| Max wkly dropi | 30.47% | 42.50% |
| Category | CRSP | EDIT |
|---|---|---|
| Company | CRISPR Therapeutics AG | Editas Medicine, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | CRISPR Therapeutics uses CRISPR-Cas9 gene editing to develop transformative medicines, led by Casgevy (exa-cel), the first CRISPR-based therapy approved by the FDA — for sickle cell disease and beta-thalassemia — developed in partnership with Vertex Pharmaceuticals. | Editas Medicine is a clinical-stage gene editing company using CRISPR-Cas9 and other gene editing tools to develop medicines, with early programs in eye disease (Leber congenital amaurosis) and hematological conditions. |
| Investor focus | Investors track Casgevy's commercial launch and patient uptake, the next wave of in vivo CRISPR programs (particularly cardiovascular), and the overall expansion of the gene editing therapy pipeline. | Investors track Editas's clinical pipeline advancement, particularly its in vivo eye disease programs, and the company's strategic focus following earlier setbacks and pipeline restructuring. |
- First company to achieve FDA approval for a CRISPR-based therapy (Casgevy for sickle cell disease and beta-thalassemia)
- Partnership with Vertex Pharmaceuticals provides commercial infrastructure and significant financial backing
- Strong cash position from Vertex partnership funding enables substantial R&D investment
- Early-mover in CRISPR gene editing with foundational IP positions
- In vivo gene editing approach (delivering CRISPR directly into the body) could be simpler to administer than ex vivo approaches if successful
- Eye disease programs provide early clinical proof-of-concept opportunities
- Casgevy's commercial uptake has been limited by complex manufacturing, treatment requirements (patient conditioning), and high price — adoption is slower than initially hoped
- Ex vivo gene editing approach requires complex bone marrow transplantation-like procedures that limit eligible patient numbers
- Competition from other gene therapies including Bluebird Bio's Lyfgenia
- No commercially approved therapies yet; all programs are pre-commercial
- Has faced clinical and operational setbacks that required pipeline restructuring
- Significantly smaller than CRISPR Therapeutics in both resources and clinical advancement
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.